SEXUAL & REPRODUCTIVE RESEARCH
Two Research Peptides, One Reproductive Question
A data-forward reading desk for the published science on kisspeptin and PT-141 — what each was actually studied for, in which populations, and how strong the evidence really is.
Kisspeptin
The upstream master switch of the reproductive hormone axis — an investigational neuropeptide that drives pulsatile LH release and has been studied in hypothalamic amenorrhea, IVF triggering and male testosterone stimulation.
Read the research →
PT-141
A central melanocortin receptor agonist that works on sexual desire circuitry in the brain — FDA-approved (as bremelanotide) for premenopausal women with HSDD, with a distinct mechanism from any vascular drug.
Read the research →The short version
Kiss Peptide is a reading desk, not a store. It collects what the published research literature actually says about two peptides studied in the context of sexual and reproductive biology: kisspeptin and PT-141 (bremelanotide). A peptide is a short chain of amino acids — the same building blocks as proteins, only far smaller. Each of these two works on a different part of the body's reproductive and sexual-response machinery, and their mechanisms do not overlap.
Kisspeptin is an upstream hormonal signal — it acts on the hypothalamus, triggering the release of a hormone cascade that ultimately drives sex-hormone production. PT-141 is a central arousal signal — it acts on melanocortin receptors in the brain's desire circuitry, shifting how the brain processes sexual motivation. One operates on the reproductive endocrine axis; the other operates on the neurological experience of desire.
This desk does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which populations, and how far that evidence really reaches. Neither is an approved reproductive-axis medicine; PT-141 is FDA-approved for one specific indication only. We do not sell anything, we do not give medical advice, and we never list a human dose.
What are research peptides?
Hormones, enzymes and signaling molecules in your body are long chains of amino acids folded into precise shapes. A peptide is a much shorter chain of the same amino acids — sometimes only three to ten links long. Because they are small and structurally specific, peptides can act like keys that fit particular receptor locks on cell surfaces, switching signaling cascades on or off.
A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, and in some cases in controlled human trials — but has either not been approved by a regulator or has a narrow approval that does not extend to all uses that appear in the literature. Material sold as a "research peptide" is for laboratory research only. Real-world effectiveness and long-term safety in general human populations is usually unestablished or established only for a narrow clinical context. When this desk reports a number, it reports it as the study did — for example, 3.2 nmol/kg subcutaneously in IVF patients — never as a recommendation for any individual.
How these two fit into reproductive research
Kisspeptin and PT-141 sit on two different points in the reproductive/sexual system, which is why reading them together is illuminating.
- Kisspeptin is the lead. It is a family of peptides encoded by the KISS1 gene that act upstream on the hypothalamic GnRH neurons — the master pacemaker of the reproductive hormone axis [2]. In human studies, it has stimulated LH release across men, healthy women, and women with hypothalamic amenorrhea [1], triggered oocyte maturation in IVF patients [3], and restored pulsatile LH secretion in amenorrhea [4]. All of this is investigational; no kisspeptin product is approved anywhere.
- PT-141 is structurally and mechanistically unrelated. It is a cyclic heptapeptide that activates melanocortin receptors (principally MC4R) concentrated in the hypothalamic and limbic circuits governing sexual desire [9]. It was studied in two large Phase 3 trials in premenopausal women with HSDD [10] and received FDA approval in 2019 — making it the only member of this desk with any regulatory approval, and then only for that narrow indication [12].
The two peptides do not act on the same target, and one being approved does not imply the other is safe or effective. Use the pages below to read each one in detail, or compare them side by side.
A note on how this desk reads the literature
Kiss Peptide is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source. Where the evidence is narrow, population-specific, or carries a significant regulatory or safety caveat, we say so plainly — that accuracy is part of the record, not a footnote to it. We describe research findings and the cited cautions that come with them; we do not recommend, prescribe, or sell. The aim is a clear, accurate account of what is known — and what is not.